SEC INSIDER TRANSACTIONS

Edwards Lifesciences Corp (EW) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

EW · Edwards Lifesciences Corp

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 28 filings · fetched 2026-11-13T17:39:21Z

Recent reported activity

0purchase rows on this page

6sale rows on this page

58matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-05-29Filed 2026-05-29	Dahl Andrew M.Officer · SVP, Corporate Controller Filing context Reported filing row; may be amended. Do not sum filings blindly. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	S Sale (market/private)Common Stock · Non-derivative	567.5266D	86.08	Direct	Form 4 ↗0001225208-26-005647
2026-05-27Filed 2026-05-27	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	23,145D	86.4201	IndirectBy Trust	Form 4 ↗0001225208-26-005610
2026-05-22Filed 2026-05-22	Chopra DaveenOfficer · CVP, TMTT & Surgical Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	1,500D	84.6035	Direct	Form 4 ↗0001225208-26-005576
2026-05-18Filed 2026-05-18	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	M Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative	620D	0	Direct	Form 4 ↗0001225208-26-005464
2026-05-18Filed 2026-05-18	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	620D	81.14	Direct	Form 4 ↗0001225208-26-005464
2026-05-18Filed 2026-05-18	Lippis Daniel J.Officer · CVP, TAVR Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	M Exercise / conversionCommon Stock · Non-derivative	620A	72.68	Direct	Form 4 ↗0001225208-26-005464
2026-05-15Filed 2026-05-18	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References:	S Sale (market/private)Common Stock · Non-derivative	8,000D	81.8216	Indirect401(k)	Form 4 ↗0001225208-26-005463
2026-05-15Filed 2026-05-18	BOBO DONALD E JROfficer · CVP,Strategy/Corp Development Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. References: F1	S Sale (market/private)Common Stock · Non-derivative	9,968D	82.0732	Direct	Form 4 ↗0001225208-26-005463

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.